Clinical Trial Update: G56W1 in Women With Postmenopausal Osteoporosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for G56W1 in postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• G56W1

Snippet

Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. | Conditions: Postmenopausal Osteoporosis | Phase 1, Phase 2 | Status: UNKNOWN